Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered DNA or RNA-targeting systems comprising a novel DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.

Abstract: Described herein are two-layer 3-D cultures, including those with microfeatures at the boundary between the two layers, as well as methods of making and using such cultures.

Abstract: Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named an PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.

Abstract: The present invention generally relates to nanowires. In one aspect, the present invention is generally directed to systems and methods of individually addressing nanowires on a surface, e.g., that are substantially upstanding or vertically-oriented with respect to the surface. In some cases, one or more nanowires may be individually addressed using various integrated circuit (“IC”) technologies, such as CMOS. For example, the nanowires may form an array on top of an active CMOs integrated circuit.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: A composite material is disclosed including: a first material including a plurality of crosslinked first polymer chains including a plurality of first polymer monomeric units; a coating layer on the surface of the first material, wherein the coating layer includes a plurality of adhesion polymer chains, wherein the plurality of adhesion polymer chains includes a plurality of the first polymer monomeric units and a plurality of first bond-forming units, wherein the adhesion polymer chains are interwoven with the first polymer chains; and a second material including a plurality of second polymer chains, wherein the coating layer is disposed in-between the first and the second material and contacting the surface of the first and the second material, and a portion of the second polymer chains includes a plurality of second polymer monomeric units and second bond-forming units; wherein the first and the second bond-forming units form one or more bonds.

Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

Abstract: The present invention generally relates to systems and methods for imaging or determining nucleic acids, for instance, within cells. In some embodiments, the transcriptome of a cell may be determined. Certain embodiments are directed to determining nucleic acids, such as mRNA, within cells at relatively high resolutions. In some embodiments, a plurality of nucleic acid probes may be applied to a sample, and their binding within the sample determined, e.g., using fluorescence, to determine locations of the nucleic acid probes within the sample. In some embodiments, codewords may be based on the binding of the plurality of nucleic acid probes, and in some cases, the codewords may define an error-correcting code to reduce or prevent misidentification of the nucleic acids. In certain cases, a relatively large number of different targets may be identified using a relatively small number of labels, e.g., by using various combinatorial approaches.

Abstract: Described herein are methods for providing an in vitro intestinal model system, e.g., using primary cells instead of cell lines and/or cancerous cells.

Abstract: A quantum computer uses interactions between atomic ensembles mediated by an optical cavity mode to perform quantum computations and simulations. Using the cavity mode as a bus enables all-to-all coupling and execution of non-local gates between any pair of qubits. Encoding logical qubits as collective excitations in ensembles of atoms enhances the coupling to the cavity mode and reduces the experimental difficulty of initial trap loading. By using dark-state transfers via the cavity mode to enact gates between pairs of qubits, the gates become insensitive to the number of atoms within each collective excitation, making it possible to prepare an array of qubits through Poissonian loading without feedback.

Abstract: Provided herein are engineered nucleic acids (e.g., expression vectors, including viral vectors, such as lentiviral vectors, adenoviral vectors, AAV vectors, herpes viral vectors, and retroviral vectors) that encode OCT4; KLF4; SOX2; or any combination thereof that are useful, for example, in inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, or any combination thereof. Also provided herein are recombinant viruses (e.g., lentiviruses, alphaviruses, vaccinia viruses, adenoviruses, herpes viruses, retroviruses, or AAVs) comprising the engineered nucleic acids (e.g.

Abstract: A system can include a wavefront-shaping device. The wavefront-shaping device can project one or more light sheets along an optical path. The one or more light sheets can include one or more light threads. Each of the one or more light threads can be non-diffracting and structured along the optical path. At least one plane of the one or more light sheets can be non-parallel to a plane of the wavefront-shaping device.

Abstract: Disclosed herein are agents that enhance muscle stem cell engraftment, as well as methods and compositions using the same.

Abstract: A previously uncharacterized gene and gene product are disclosed herein that increase blood glucose clearance independent of insulin. Also described is a methodology for enriching for mRNAs transcribing excreted and membrane bound proteins as well as a non-human animal expressing a labeled SEC61b protein.

Abstract: A textile actuator worn by a user comprises a textile envelope that defines a chamber made fluid-impermeable by a fluid-impermeable bladder contained in the textile envelope and/or a fluid-impermeable structure incorporated into the textile envelope. The textile envelope has a pre-determined geometry that produces an equilibrium state at a non-180-angle displacement and that stops further displacement upon pressurization of the chamber and prevents over-extension the joint. A fluid is delivered into or out of the chamber to displace the textile envelope primarily by transitioning from an uninflated state to the pre-determined geometry due to displacement of the textile envelope rather than via stretching or contraction of the textile envelope. When actuated, the textile actuator (a) displaces a body segment of the user and/or (b) supports and holds the body segment of the user in place.

Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

Abstract: The technology described herein is directed to a gene regulatory element, e.g., enhancer, vectors comprising the same, adeno-associated vectors comprising the same and cells comprising said vectors. In another aspect, described herein are methods of treating a motor neuron disease or disorder comprising administration of said vectors, e.g., AAV vectors. In another aspect, described herein are nucleic acid compositions comprising the gene regulatory element as described herein.

Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.

Abstract: Provided herein are pluripotent stem cells comprising particular combinations of transcription factor for the production of oligodendrocyte progenitor cells (OPCs). Also provided herein are methods of producing the pluripotent stem cells and methods of using the pluripotent stem cells to produce (OPCs) and oligodendrocytes.

Abstract: A nanopore sensor includes a nanopore disposed in a support structure with a nanopore diameter and having a nanopore fluidic resistance, RPore. A fluidic passage, is disposed in fluidic connection between a first fluidic reservoir of ionic concentration solution and the nanopore, and includes a passage length having a fluidic passage width, along at least a portion of a fluidic passage length, that is greater than the diameter of the nanopore and less than the fluidic passage length. The fluidic passage has a fluidic passage fluidic resistance, RFP, of at least about 10% of the nanopore fluidic resistance, RPore, and no more than about 10 times the nanopore fluidic resistance, RPore. The nanopore is disposed in fluidic connection between the fluidic passage and a second fluidic reservoir of ionic concentration solution. At least one transistor is operatively connected electrically to sense electrical potential local to the fluidic passage.